YARW

Yarrow Bioscience Inc (YARW) 10Y Growth Potential Analysis (2026)

Invetso Score: 3.1/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 3.2 (Weak)

No five-year revenue CAGR is available, so there is no verified evidence of durable top-line compounding versus peers.

Very low EV-to-EBITDA suggests the market is pricing limited earnings power, which usually aligns with weaker long-term revenue scalability than peers.

Negative ROIC indicates reinvested capital has not yet translated into value-accretive expansion, reducing confidence in repeatable growth compounding.

R&D intensity above 20% of revenue can support product development, but peer comparison is weak without proof of monetized revenue conversion.

Market Tailwinds

Score:

No disclosed segment concentration or market-share data limits evidence that YARW benefits from identifiable demand tailwinds stronger than peers.

Absent revenue CAGR disclosure, there is no proof that end-market demand has consistently translated into scalable sales growth.

Negative sales multiple and negative free-cash-flow yield imply the business is not yet capturing market expansion in a durable, compounding way.

Compared with peers showing measurable multi-year growth, YARW currently lacks verified indicators of structurally favorable market pull.

Scalability Expansion

Score:

Capex-to-revenue at zero suggests limited asset-heavy expansion needs, but that alone does not prove scalable revenue growth versus peers.

Negative cash conversion cycle is unusually favorable, yet the extreme figure may reflect working-capital mechanics rather than durable operating scalability.

High R&D spend can enable future expansion, but without revenue or EPS CAGR evidence, scalability remains unproven relative to peers.

Net debt to EBITDA above 1.2x leaves some reinvestment flexibility, although weak profitability still constrains compounding capacity.

Constraints Limitations

Score:

Negative TTM ROIC is the clearest structural constraint because it shows current capital deployment is not generating scalable returns.

Interest coverage of zero indicates limited earnings support for expansion, which weakens long-term growth durability versus healthier peers.

Negative free-cash-flow yield signals that internal funding for reinvestment is not yet established, constraining self-financed growth.

Missing multi-year growth history and segment data create visibility gaps, but the larger issue is weak proof of monetized scaling.

Overall Score

Score:

YARW shows some reinvestment activity and working-capital efficiency, but negative ROIC and absent verified growth history indicate structurally weak long-term compounding versus peers.

Score Driver: Negative Roic

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Yarrow Bioscience Inc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →